

Remarks

Support for Amendments to Claims:

Support for new claims 40 to 46 is found on at least the following pages:

Example 54, page 43, lines 24-25: (7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-pyrrolidin-3-ol;

Example 71, page 53, line 35 spanning to page 54, line 2: (7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

Example 90, page 64, lines 6-8: (7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

Example 91, page 64, lines 23-25: (7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

Example 92, page 65, lines 8-10: (7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-piperidin-4-ol;

Example 94, page 66, lines 9-11: (7R, 9aS)-trans-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine; and

Example 101, Page 69, lines 6-8: (7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine.

New claims 40 to 46 do not add new matter.

Conclusion

Applicants request that the 312 Amendments be allowed. If Examiner has any questions concerning this request, Examiner is invited to contact the below-signed attorney. It is believed that no fee due; however, if there is a fee due, please charge any payment or credit any overpayment to Charge Account 16-1445.

Respectfully submitted,

_____/Mary J. Hosley/_____
Mary J. Hosley, Attorney, Registration No. 48,324

Date: _____24 April 2006_____

Pfizer, Inc
150 East 42nd Street, Floor 5
New York, NY 10017-5612
Telephone No. 212.733-0460
Telefax No. 212.573-1939